Second primary malignancy risk in thyroid cancer survivors: A systematic review and meta-analysis

Thyroid

Volumn 17, Issue 12, 2007, Pages 1277-1288

  Subramanian, Shoba ^a   Goldstein, David P ^b   Parlea, Luciana ^c   Thabane, Lehana ^d,e   Ezzat, Shereen ^f,g,h,i   Ibrahim Zada, Irada ^b   Straus, Sharon ^c,j   Brierley, James D ^b   Tsang, Richard W ^b   Gafni, Amiram ^d,k   Rotstein, Lorne ^b   Sawka, Anna M ^f,l  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g MOUNT SINAI HOSPITAL   (Canada)

^h Freeman Centre for Endocrine Oncology   (Canada)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

^j UNIVERSITY OF CALGARY   (Canada)

^k MCMASTER UNIVERSITY   (Canada)

^l TORONTO GENERAL HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ADRENAL GLAND; BONE; BRAIN; BREAST; CANCER RISK; CENTRAL NERVOUS SYSTEM; COLON; CONFIDENCE INTERVAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; JOINT; KIDNEY; LEUKEMIA; LUNG CANCER; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSTATE; REVIEW; SALIVARY GLAND; SECOND CANCER; SOFT TISSUE SARCOMA; STOMACH; SYSTEMATIC REVIEW; THYROID CANCER; UTERINE CERVIX CANCER;

CHEMOTHERAPY, ADJUVANT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY, ADJUVANT; RISK FACTORS; THYROID NEOPLASMS;

EID: 37849036038     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0171     Document Type: Review

References (43)

1. Canadian Cancer Society, National Cancer Institute of Canada, Statistics Canada, Public Health Agency of Canada. Canadian Cancer Statistics 2005. Available at http://www.cancer.ca. Accessed August 2, 2005.
2. Hayat MJ, Howlader N, Reichman E, Edwards BK 2007 Cancer statistics, trends, and multiple primary cancers from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 12:20-37.
3. Davies L, Welch HG 2006 Epidemiology of head and neck cancer in the United States. Otolaryngol Head Neck Surg 135(3):451-457.
4. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI 2006 Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16(12):1229-1242.
5. Hay ID 2006 Selective use of radioactive iodine in the post-operative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol 94:692-700.
6. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC 2004 Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89(8):3668-3676.
7. Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scelo G, Pukkala E, Hemminki K, Anderson A, Tracey E, Friis S, McBride ML, Kee-Seng C, Pompe-Kirn V, Kliewer EV, Tonita JM, Jonasson JG, Martos C, Boffetta P, Brennan P 2006 Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab 91(5):1819-1825.
8. Canchola AJ, Horn-Ross PL, Purdie DM 2006 Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol 163(6):521-527.
9. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M 2003 Second primary malignancies in thyroid cancer patients. Br J Cancer 89(9):1638-1644.
10. Hemminki K, Jiang Y 2001 Second primary neoplasms after 19281 endocrine gland tumours: aetiological links? Eur J Cancer 37(15):1886-1894.
11. Edhemovic I, Volk N, Auersperg M 1998 Second primary cancers following thyroid cancer in Slovenia. A population-based cohort study. Eur J Cancer 34(11):1813-1814.
12. de Vathaire F, Schlumberger M, Delisle MJ, Francese C, Challeton C, de la Genardiere E, Meunier F, Parmentier C, Hill C, Sancho-Garnier H 1997 Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer 75(5):734-739.
13. Hall P, Boice JD Jr., Berg G, Bjelkengren G, Ericsson UB, Hallquist A, Lidberg M, Lundell G, Mattsson A, Tennvall J, Wiklund K, Holm LE 1992 Leukaemia incidence after iodine-131 exposure. Lancet 340(8810):1-4.
14. Akslen LA, Glattre E 1992 Second malignancies in thyroid cancer patients: a population-based survey of 3658 cases from Norway. Eur J Cancer 28(2-3):491-495.
15. Hall P, Holm LE, Lundell G 1990 Second primary tumors following thyroid cancer. A Swedish record-linkage study. Acta Oncol 29(7):869-873.
16. Ron E, Curtis R, Hoffman DA, Flannery JT 1984 Multiple primary breast and thyroid cancer. Br J Cancer 49(1):87-92.
17. Hall P, Holm L-E 1995 Cancer in iodine-131 exposed patients. J Endocrinol Invest 18(2):147-149.
18. Hall P, Holm LE, Lundell G, Ruden BI 1992 Tumors after radiotherapy for thyroid cancer. A case-control study within a cohort of thyroid cancer patients. Acta Oncol 31(4):403-407.
19. Rubino C, Adjadj E, Doyon F, Shamsaldin A, Abbas TM, Caillou B, Colonna M, Cecarreli C, Schvartz C, Bardet S, langlois C, Ricard M, Schlumberger M, de Vathaire F 2005 Radiation exposure and familial aggregation of cancers as risk factors for colorectal cancer after radioiodine treatment for thyroid carcinoma. Int J Radiat Oncol Biol Phys 62(4):1084-1089.
20. Chuang SC, Hashibe M, Yu GP, Le AD, Cao W, Hurwitz EL, Rao JY, Neugut AI, Zhang ZF 2006 Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers. Cancer Lett 238(1):42-52.
21. Hrafnkelsson J, Tulinius H, Jonasson JG, Olafsdottir G, Sigvaldason H 1989 Papillary thyroid carcinoma in Iceland. A study of the occurrence in families and the coexistence of other primary tumours. Acta Oncol 28(6):785-788.
22. Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR, Vassilopoulou-Sellin R 2001 The development of breast carcinoma in women with thyroid carcinoma. Cancer 92(2):225-231.
23. Li CI, Rossing MA, Voigt LF, Daling JR 2000 Multiple primary breast and thyroid cancers: role of age at diagnosis and cancer treatments (United States). Cancer Causes Control 11(9):805-811.
24. Osterlind A, Olsen JH, Lynge E, Ewertz M 1985 Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Denmark, 1943-80. Natl Cancer Inst Monogr 68:361-388.
25. Tucker MA, Boice JD Jr., Hoffman DA 1985 Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935-82. Natl Cancer Inst Monogr 68:161-189.
26. Brincker H, Hansen HS, Andersen AP 1973 Induction of leukemia by 131-I treatment of thyroid carcinoma. Br J Cancer 28(3):232-237.
27. Hall P, Holm LE, Lundell G, Bjelkengren G, Larsson LG, Lindberg S, Tennvall J, Wicklund H, Boice JD, Jr . 1991 Cancer risks in thyroid cancer patients. Br J Cancer 64(1):159-163.
28. Emrich D, Creutzig H 1988 Benefits and risks of radioactive iodine therapy in differentiated thyroid carcinoma. Prog Surg 19:133-146.
29. Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL 1984 Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 57(676):323-327.
30. Holm LE, Wiklund KE, Lundell GE, Bergman NA, Bjelkengren G, Cederquist ES, Ericsson UB, Larsson LG, Lidberg ME, Lindberg RS, Wicklund HV, Boice JD Jr. 1988 Thyroid cancer after diagnostic doses of iodine-131: a retrospective cohort study. J Natl Cancer Inst 80(14):1132-1138.
31. Jazbec J, Ecimovic P, Jereb B 2004 Second neoplasms after treatment of childhood cancer in Slovenia. Pediatr Blood Cancer 42(7):574-581.
32. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L 1995 Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 36(1):21-27.
33. Vassilopoulou-Sellin R, Palmer L, Taylor S, Cooksley CS 1999 Incidence of breast carcinoma in women with thyroid carcinoma. Cancer 85(3):696-705.
34. Ishikawa K, Noguchi S, Tanaka K, Fukuda A, Hirohata T 1996 Second primary neoplasms in thyroid cancer patients. Jpn J Cancer Res 87(3):232-239.
35. Edmonds CJ, Smith T 1986 The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 59(697):45-51.
36. Johns ME, Shikhani AH, Kashima HK, Matanoski GM 1986 Multiple primary neoplasms in patients with salivary gland or thyroid gland tumors. Laryngoscope 96(7):718-721.
37. Sadetzki S, Calderon-Margalit R, Peretz C, Novikov I, Barchana M, Papa MZ 2003 Second primary breast and thyroid cancers (Israel). Cancer Causes Control 14(4):367-375.
38. Verkooijen RB, Smit JW, Romijn JA, Stokkel MP 2006 The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrinol 155(6):801-806.
39. Ronckers CM, McCarron P, Ron E 2005 Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 117(2):281-288.
40. Glanzmann C 1992 Subsequent malignancies in patients treated with 131-iodine for thyroid cancer. Strahlenther Onkol 168(6):337-343.
41. Berthe E, Henry-Amar M, Michels JJ, Rame JP, Berthet P, Babin E, Icard P, Samama G, Galateau-Salle F, Mahoudeau J, Bardet S 2004 Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 31(5):685-691.
42. Adjadj E, Rubino C, Shamsaldim A, Le MG, Schlumberger M, de Vathaire F 2003 The risk of multiple primary breast and thyroid carcinomas. Cancer 98(6):1309-1317.
43. Schlumberger M, Challeton C, de Vathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M, Parmentier C 1996 Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37(4):598-605.